Persistent cellular immunity to SARS-CoV-2 infection
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
SARS-CoV-2 is responsible for an ongoing pandemic that has affected millions of individuals around the globe. To gain further understanding of the immune response in recovered individuals, we measured T cell responses in paired samples obtained an average of 1.3 and 6.1 mo after infection from 41 individuals. The data indicate that recovered individuals show persistent polyfunctional SARS-CoV-2 antigen–specific memory that could contribute to rapid recall responses. Recovered individuals also show enduring alterations in relative overall numbers of CD4+ and CD8+ memory T cells, including expression of activation/exhaustion markers, and cell division.
Article activity feed
-
-
SciScore for 10.1101/2020.12.08.416636: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable female). Table 2: Resources
Antibodies Sentences Resources Cell Stimulation and intracellular staining: Cells were stimulated for 12h with SARS-CoV-2 peptide pools (0.25 μg/ml) in the presence of αCD28/αCD49d co-stimulatory antibodies (BD FastImmune™, BD Biosciences, San Diego, CA, USA), 5 μg/ml brefeldin A (Sigma-Aldrich, St-Louis, MO, USA) and 5 μg/ml Monensin. (BD GolgiStop™ BD Biosciences, San Diego, CA, USA), and anti-CD107a-PE-Cy5 (Clone H4A3) (the staining for CD107a is carried out during cell activation in this assay). Monensinsuggested: Noneanti-C…SciScore for 10.1101/2020.12.08.416636: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable female). Table 2: Resources
Antibodies Sentences Resources Cell Stimulation and intracellular staining: Cells were stimulated for 12h with SARS-CoV-2 peptide pools (0.25 μg/ml) in the presence of αCD28/αCD49d co-stimulatory antibodies (BD FastImmune™, BD Biosciences, San Diego, CA, USA), 5 μg/ml brefeldin A (Sigma-Aldrich, St-Louis, MO, USA) and 5 μg/ml Monensin. (BD GolgiStop™ BD Biosciences, San Diego, CA, USA), and anti-CD107a-PE-Cy5 (Clone H4A3) (the staining for CD107a is carried out during cell activation in this assay). Monensinsuggested: Noneanti-CD107a-PE-Cy5suggested: NoneViability Stain, BD Biosciences, San Diego, CA, USA) and a 29-color cocktail of monoclonal antibodies (mAbs) containing surface antibodies against CD19 (Clone SJ25C1), CD19suggested: NoneThe cells were then washed with PBS containing 2% FBS and permeabilized according to the manufacturer’s instructions using a Foxp3/Transcription Factor Staining Buffer Set (eBioscience™) and stained with intracellular antibodies against CD3 (Clone SK7), CD3suggested: NoneSoftware and Algorithms Sentences Resources High-dimensional data analysis of flow cytometry data: viSNE and FlowSOM analyses were performed on Cytobank (https://cytobank.org). viSNE analysis was performed using equal sampling of 5000 cells (for total T cell phenotyping analysis, Fig. 1), or proportional sampling (for antigen-specific CD4+ T cell analysis, Fig. 3) from each FCS file, with 7500 iterations, a perplexity of 30, and a theta of 0.5. FlowSOMsuggested: (FlowSOM, RRID:SCR_016899)Cytobanksuggested: (Cytobank, RRID:SCR_014043)Statistical analysis: Statistical analyses were performed using Prism 7.0 (GraphPad). Prismsuggested: (PRISM, RRID:SCR_005375)GraphPadsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
